BioSpace News Archive

According to Nova one advisor, during the forecast period of 2022 to 2030, the global ACL Reconstruction Procedures market is estimated to develop at a strong growth rate.

Santhera Pharmaceuticals has updated its corporate calendar. The Company will publish its 2021 AnnualReport onJune 10, 2022 andhold its Annual General Meeting on June 30, 2022.

The global CAR T-Cell Therapy market is estimated to develop at a compound annual growth rate (CAGR) of 31.2%.

DarioHealth Corp., a leader in the global digital therapeutics market, announced three new research studies presented at the American Diabetes Association’s 82nd Scientific Sessions being held June 3rd to 7th, 2022 in New Orleans, Louisiana.

BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held June 3 – 7, 2022, at McCormick Place Convention Center in Chicago, IL.

ReCode Therapeutics , a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics will present a corporate overview on Friday, June 10th from 11:00 - 11:25 a.m. ET at the Jefferies Healthcare Conference being held in New York, NY from June 8-10, 2022.

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology.

Scorpion Therapeutics, Inc. (“Scorpion Therapeutics”), a pioneering oncology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion Therapeutics, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in New York City.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate LB1908 in a Phase 1 clinical trial in the United States.

Surgalign Holdings, Inc. announced that it has granted restricted stock unit awards to five employees, none of whom was an executive officer, as an inducement for them to accept employment with Surgalign, and representing the right to receive, in the aggregate, up to 27,877 shares of Surgalign common stock.